Glycogen synthase kinase 3β (GSK-3β) is a widely investigated molecular target for numerous diseases including Alzheimer's disease, cancer, and diabetes mellitus. Inhibition of GSK-3β activity has become an attractive approach for treatment of diabetes and cancer. We report the discovery of novel GSK-3β inhibitors of 3-arylidene-2-oxindole scaffold with promising activity. The most potent compound
糖原合酶激酶3β(GSK-3β)是许多疾病的分子靶标,包括阿尔茨海默氏病,癌症和糖尿病。抑制GSK-3β活性已成为治疗糖尿病和癌症的一种有吸引力的方法。我们报告发现具有前途活性的3-亚芳基-2-氧
吲哚支架的新型GSK-3β
抑制剂。最有效的化合物3a抑制GSK-3β,IC50为4.19 nM。在基于细胞的测定中,3a在10 µM时无明显白细胞毒性,对A549细胞具有中等程度的细胞毒性。化合物3a在肥胖的链
脲佐菌素治疗的大鼠中表现出很高的抗糖尿病功效,以50 mg / kg体重的剂量改善了
葡萄糖耐量,因此代表了进一步优化的有趣线索。